DE60142500D1 - Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon - Google Patents

Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon

Info

Publication number
DE60142500D1
DE60142500D1 DE60142500T DE60142500T DE60142500D1 DE 60142500 D1 DE60142500 D1 DE 60142500D1 DE 60142500 T DE60142500 T DE 60142500T DE 60142500 T DE60142500 T DE 60142500T DE 60142500 D1 DE60142500 D1 DE 60142500D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
signal transduction
antibodies against
human monoclonal
costimulatory signal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142500T
Other languages
English (en)
Inventor
Tsuji Takashi
Tezuka Katsunari
Hori Nobuaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Application granted granted Critical
Publication of DE60142500D1 publication Critical patent/DE60142500D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DE60142500T 2000-05-18 2001-05-18 Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon Expired - Lifetime DE60142500D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000147116 2000-05-18
JP2001099508A JP3597140B2 (ja) 2000-05-18 2001-03-30 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途

Publications (1)

Publication Number Publication Date
DE60142500D1 true DE60142500D1 (de) 2010-08-19

Family

ID=26592169

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60142500T Expired - Lifetime DE60142500D1 (de) 2000-05-18 2001-05-18 Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon

Country Status (29)

Country Link
US (4) US6803039B2 (de)
EP (3) EP1158004B1 (de)
JP (1) JP3597140B2 (de)
KR (2) KR20050008858A (de)
CN (1) CN100482688C (de)
AR (2) AR028927A1 (de)
AT (1) ATE473243T1 (de)
AU (3) AU773625B2 (de)
BR (2) BRPI0106646B1 (de)
CA (3) CA2722134A1 (de)
CY (1) CY1110816T1 (de)
CZ (1) CZ302902B6 (de)
DE (1) DE60142500D1 (de)
DK (1) DK1158004T3 (de)
ES (1) ES2347758T3 (de)
HK (1) HK1043371B (de)
HU (1) HU230770B1 (de)
IL (3) IL147448A0 (de)
MX (1) MXPA02000687A (de)
MY (1) MY137640A (de)
NO (1) NO333921B1 (de)
NZ (2) NZ533324A (de)
PE (1) PE20011337A1 (de)
PT (1) PT1158004E (de)
SG (4) SG187990A1 (de)
SK (1) SK287862B6 (de)
TR (3) TR200202736T1 (de)
TW (2) TWI304811B (de)
WO (1) WO2001087981A2 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
WO2004003544A1 (en) * 2002-06-26 2004-01-08 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
JP5105874B2 (ja) * 2003-07-18 2012-12-26 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合因子
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2005103086A1 (en) * 2004-04-23 2005-11-03 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
US7397250B2 (en) * 2004-11-12 2008-07-08 Baker Hughes Incorporated High resolution resistivity earth imager
US7385401B2 (en) 2005-07-08 2008-06-10 Baker Hughes Incorporated High resolution resistivity earth imager
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7365545B2 (en) 2005-12-29 2008-04-29 Baker Hughes Incorporated Two-axial pad formation resistivity imager
US20100015143A1 (en) * 2006-03-22 2010-01-21 Tracy Hussell Compositions and Methods Relating to Modulation of Immune System Components
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
RU2549701C2 (ru) * 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
WO2009009114A2 (en) * 2007-07-12 2009-01-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
US8174266B2 (en) * 2008-07-23 2012-05-08 Baker Hughes Incorporated Multi-resolution borehole resistivity imaging
US8390294B2 (en) * 2008-07-23 2013-03-05 Baker Hughes Incorporated Multi-resolution borehole resistivity imaging
US20110293605A1 (en) * 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
US8815242B2 (en) * 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
WO2011020024A2 (en) * 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
CA2772084C (en) 2009-08-27 2016-10-18 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
US9133436B2 (en) 2010-02-04 2015-09-15 The Trustees Of The University Of Pennsylvania ICOS critically regulates the expansion and function of inflammatory human Th17 cells
EP3590969A1 (de) 2011-03-31 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Gegen icos gerichtete antikörper und verwendungen davon
EP3559049A4 (de) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Polypeptidkonstrukte und anwendungen davon
RS58528B1 (sr) 2012-12-03 2019-04-30 Bristol Myers Squibb Co Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9950035B2 (en) * 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
WO2015081253A1 (en) 2013-11-26 2015-06-04 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
SI3273992T1 (sl) * 2015-03-23 2020-09-30 Jounce Therapeutics, Inc. Protitelesa proti ICOS
EP3322431A2 (de) 2015-07-16 2018-05-23 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
CN107921084B (zh) * 2015-07-31 2022-04-29 脉管生物生长有限公司 含有活动精子结构域的蛋白质2和炎症
ES2839456T3 (es) 2015-07-31 2021-07-05 Vascular Biogenics Ltd Proteína 2 que contiene el dominio del esperma móvil y del cáncer
EP3798234A1 (de) 2015-09-02 2021-03-31 Immutep S.A.S. Agonistische anti-lag-3 antikörper
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JP6886854B2 (ja) * 2017-04-13 2021-06-16 シスメックス株式会社 被検物質の情報取得方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US10981992B2 (en) * 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (de) 2017-12-19 2020-10-28 Kymab Limited Bispezifischer antikörper für icos und pd-l1
EP3502140A1 (de) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
TWI829679B (zh) * 2018-03-26 2024-01-21 美商再生元醫藥公司 用於測試治療藥劑之人類化囓齒動物
EP3806848A2 (de) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Erhöhung der immunaktivität durch modulation von postzellulären signalisierungsfaktoren
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
WO2022053985A1 (en) 2020-09-10 2022-03-17 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 antibodies and methods of use thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH642458A5 (en) 1980-04-25 1984-04-13 Hoffmann La Roche Immunological method
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
JP2615456B2 (ja) 1987-11-13 1997-05-28 松下電器産業株式会社 スピーカシステム
DE122006000007I1 (de) 1987-12-31 2006-04-27 Tanox Biosystems Inc Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3162438B2 (ja) 1991-09-12 2001-04-25 住友製薬株式会社 高感度特異的抗体測定法
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
WO1995024217A1 (en) 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5747461A (en) 1994-07-26 1998-05-05 Markov; Angel K. Synergistic administration of cyclosporine and fructose diphosphate
JP3580948B2 (ja) 1995-05-02 2004-10-27 日本たばこ産業株式会社 ヒト由来ｃｅｔｐに反応性を有するモノクローナル抗体及びヒト由来ｃｅｔｐの定量方法
EP1297847A3 (de) 1996-01-23 2003-05-07 Genentech, Inc. Antikörper gegen CD18 bei Gehirnschlag
US5914112A (en) 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
PT928197E (pt) 1996-09-18 2003-06-30 Zetesis Spa Utilizacao de proteinas como agentes contra doencas de natureza autoimunitaria
EP1007090B1 (de) 1996-11-08 2009-12-30 Biogen Idec Inc. Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)
WO1998037415A1 (en) 1997-02-20 1998-08-27 The Regents Of The University Of California ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9704174D0 (en) 1997-02-28 1997-04-16 Univ Birmingham Agent for medical treatment
EP0973804B1 (de) 1997-04-07 2006-12-27 Genentech, Inc. Anti-vefg antibodies
JP2002505673A (ja) 1997-06-12 2002-02-19 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Ｃｄ２８／ｃｔｌａ−４阻害性ペプチド模倣物、それらの医薬組成物、およびそれらを使用する方法
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US7259247B1 (en) * 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies
US6297022B1 (en) * 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
JPH11228442A (ja) 1998-02-09 1999-08-24 Cypros Pharmaceut Corp 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
AU767241B2 (en) 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
JP2000154151A (ja) 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
JP2003532370A (ja) 1998-10-07 2003-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規なＴｈ２特異的分子およびその使用方法
SI2332976T1 (sl) * 1999-02-03 2014-08-29 Amgen Inc. Novi polipeptidi, vkljuäśeni v imunskem odgovoru
IL146106A0 (en) 1999-05-06 2002-07-25 Genetics Inst Use of soluble costimulatory molecules to enhance immune responses
AU6615500A (en) 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
WO2001012658A2 (en) 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
DE60035517T2 (de) 1999-09-21 2008-03-20 Genetics Institute, LLC, Cambridge Gl50 moleküle, sowie verwendungen derselben
EP1224201A4 (de) 1999-10-29 2005-03-02 Human Genome Sciences Inc 32 vom menschen abgesonderte proteine
WO2001064704A1 (en) 2000-03-02 2001-09-07 Mayo Foundation For Medical Education And Research hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4236925B2 (ja) 2000-11-28 2009-03-11 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤

Also Published As

Publication number Publication date
US6803039B2 (en) 2004-10-12
NO20020263D0 (no) 2002-01-17
EP1158004A3 (de) 2002-07-24
TWI304811B (en) 2009-01-01
CN100482688C (zh) 2009-04-29
SG165161A1 (en) 2010-10-28
IL207060A0 (en) 2010-12-30
NZ516411A (en) 2004-08-27
MY137640A (en) 2009-02-27
US20120039874A1 (en) 2012-02-16
CA2344086A1 (en) 2001-11-18
AR058366A2 (es) 2008-01-30
IL147448A0 (en) 2002-08-14
AU773625B2 (en) 2004-05-27
IL147448A (en) 2011-01-31
JP3597140B2 (ja) 2004-12-02
ES2347758T3 (es) 2010-11-04
CY1110816T1 (el) 2015-06-10
SK287862B6 (sk) 2012-02-03
WO2001087981A3 (en) 2002-06-13
NO333921B1 (no) 2013-10-21
HUP0202532A2 (hu) 2002-11-28
KR100609442B1 (ko) 2006-08-03
HUP0202532A3 (en) 2005-07-28
SG153626A1 (en) 2009-07-29
US20080199466A1 (en) 2008-08-21
TW200825171A (en) 2008-06-16
TR200202736T1 (tr) 2005-06-21
CA2635963C (en) 2011-01-25
BRPI0106646B1 (pt) 2018-02-14
WO2001087981A2 (en) 2001-11-22
EP1158004A2 (de) 2001-11-28
CZ200254A3 (cs) 2002-06-12
US7166283B2 (en) 2007-01-23
HK1043371A1 (en) 2002-09-13
EP2295467A1 (de) 2011-03-16
US20020102658A1 (en) 2002-08-01
PT1158004E (pt) 2010-10-04
KR20020026542A (ko) 2002-04-10
BR0106646A (pt) 2002-04-16
NO20020263L (no) 2002-03-18
DK1158004T3 (da) 2010-08-16
TR200200781T1 (tr) 2003-02-21
NZ533324A (en) 2005-07-29
TR200202735T1 (tr) 2005-04-21
CA2722134A1 (en) 2001-11-18
EP1158004B1 (de) 2010-07-07
IL207060A (en) 2017-02-28
KR20050008858A (ko) 2005-01-21
SG187990A1 (en) 2013-03-28
ATE473243T1 (de) 2010-07-15
JP2002034581A (ja) 2002-02-05
AU5674701A (en) 2001-11-26
SG135917A1 (en) 2007-10-29
PE20011337A1 (es) 2002-01-02
AU2004201697A1 (en) 2004-05-20
SK2412002A3 (en) 2002-07-02
TWI316546B (en) 2009-11-01
CA2635963A1 (en) 2001-11-18
US20040180052A1 (en) 2004-09-16
HK1043371B (zh) 2010-10-08
EP2216343A1 (de) 2010-08-11
CN1439022A (zh) 2003-08-27
HU230770B1 (hu) 2018-03-28
MXPA02000687A (es) 2004-08-12
CA2344086C (en) 2009-02-10
AU4388101A (en) 2001-11-22
AR028927A1 (es) 2003-05-28
CZ302902B6 (cs) 2012-01-11
US7988965B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
DE60142500D1 (de) Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon
CY2019022I2 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CY2019018I1 (el) Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY2012002I1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
FR16C1012I2 (fr) Utilisation therapeutique d'anticorps anti-cs1
CY2014046I2 (el) Αντισωμα το οποιο δεσμευει αλφα4βητα7 ιντεγκρινη και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
ATE426616T1 (de) Antikírper gegen menschliches mcp-1
CY2013032I1 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
DE60029115D1 (de) Antigen enthaltende pharmazeutische zusammensetzung
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
ATE549033T1 (de) Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
DE60038304D1 (de) Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
DE60115698D1 (de) Medikamentenspender
DE69812433D1 (de) Anti-estrogene steroide, pharmazeutische zusammensetzungen und verwendungen davon
IS5696A (is) Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
ATE553129T1 (de) Antikörper gegen humanes il-12
ZA200200011B (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof.
FR2850377B1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2873690B1 (fr) Derives d'oxopiperidine, leur preparation et leur application en therapeutique
ATE362490T1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
FR2873693B1 (fr) Derives d'amino-tropane, leur preparation et leur application en therapeutique
DE60214533D1 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen
DE60137952D1 (de) Pharmazeutische zusammensetzungen mit epinastin und pseudoephedrin
DE60014616D1 (de) Antikörper gegen plazentaprotein 13